Roche Therapeutics, Inc v GenRx Pty Ltd

Link copied
Case Copied 55 min read

FEDERAL COURT OF AUSTRALIA

Roche Therapeutics, Inc v GenRx Pty Ltd [2007] FCA 83

INTELLECTUAL PROPERTY – pharmaceutical patent – interlocutory hearing seeking injunctions to prevent alleged infringement – whether serious question to be tried as to whether there will be infringement – whether patent is invalid – whether impugned products would infringe patent even if valid – where balance of convenience lies

National Health Act 1953 (Cth)
Patents Act 1990 (Cth) ss 7, 18, 117, 138
Therapeutic Goods Act 1989 (Cth)

Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) 50 FCR 1 referred to
Gillette Safety Razor Company v Anglo-American Trading Co Ltd (1913) 30 RPC 465 referred to
Hexal Australia Pty Limited v Roche Therapeutics Inc [2005] FCA 1218 referred to
Re BA’s Application (1915) 32 RPC 348 referred to
Rescare Limited v Anaesthetic Supplies Pty Limited (1992) 25 IPR 119 referred to

Macquarie Dictionary, 4th ed, Macquarie University, 2005
Shorter Oxford English Dictionary, 5th ed, Oxford University, 2002

Gilbert EM, Olsen SL, Mealey P, Volkman K, Garrabee P, and Bristow MR “Is beta-receptor up-regulation necessary for improved LV function in dilated cardiomyopathy?”  (Paper presented at EMH Milan, 1991).
Kelly DT, “Carvedilol in Heart Failure”, Cardiology 1993, 82 (Suppl 3). 45-59.
Metra M, Nardi M, Giubbini R, Dei Cas L, “Effects of Short- and Long- Term Carvedilol Administration on Rest and Exercise Hemodynamic Variables, Exercise Capacity and Clinical Conditions in Patients with Idiopathic Dilated Cardiomyopathy” J Am Coll Cardiol vol 24, no 7, 1994.

ROCHE THERAPEUTICS, INC & ORS v GENRX PTY LTD

NSD2429 OF 2006

EMMETT J
9 FEBRUARY 2007
SYDNEY


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD2429 OF 2006

BETWEEN:

ROCHE THERAPEUTICS, INC
First Applicant

F HOFFMAN-LA ROCHE AG
Second Applicant

ROCHE PRODUCTS PTY LTD
Third Applicant

AND:

GENRX PTY LTD
Respondent

JUDGE:

EMMETT J

DATE OF ORDER:

9 FEBRUARY 2007

WHERE MADE:

SYDNEY

THE COURT:

1.Notes the following undertakings given to the Court by the respondent until further order:

(a)Not to advertise or otherwise promote carvedilol for decreasing mortality resulting from congestive heart failure provided that it will not be a breach of this undertaking for the respondent to advertise or otherwise promote carvedilol in connection with:

(i)Product Information Sheet in the form of Exhibit 1A upon request prior to the approval (if granted) of the Product Information in the form of Exhibit AMK-2; or

(ii)       Consumer Medicine Information in the form of Exhibit RM-7.

(b)To prosecute its application for the approval of its Product Information Sheet in the form of Exhibit AMK-2 expeditiously and to inform the applicants at the end of 21 days of the progress of the application.

(c)Not to provide any discount or material benefit to purchasers of carvedilol which is tied to the purchase of any other medicament which is also supplied by any of the applicants in Australia.

(d)Not to provide any discount or material benefit to purchasers of any other medicament which is…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Roche Therapeutics, Inc v GenRx Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2007] FCA 83
Decision Date

CaseChat Overview and Summary

In the Federal Court of Australia, Roche Therapeutics, Inc sought interlocutory relief against GenRx Pty Ltd for alleged patent infringement concerning carvedilol, a pharmaceutical used in the treatment of congestive heart failure. The dispute centred on whether GenRx's promotion and sale of carvedilol infringed on Roche's patents and whether Roche was entitled to an interlocutory injunction to prevent further infringement.

The primary legal issues revolved around whether there was a serious question to be tried regarding the infringement of Roche's patents, and where the balance of convenience lay in granting interlocutory relief. The court had to consider whether the proposed undertakings by GenRx sufficiently protected Roche's interests and whether such relief was warranted at the interlocutory stage.

The Court found that GenRx's undertakings provided adequate protection to Roche's interests, including not advertising carvedilol for reducing mortality except when supplying the unamended product information sheet, maintaining sales records, and ensuring timely prosecution of their application for product information approval. The court concluded that these measures, combined with the balance of convenience, justified the refusal of further interlocutory relief. However, Roche was granted liberty to reapply if circumstances changed significantly. The court also ruled that GenRx's costs of the interlocutory application should be borne by GenRx, without additional orders regarding the costs.

Consequently, upon GenRx providing the specified undertakings, Roche's application for interlocutory relief beyond these undertakings was to be refused. This decision balanced the need to protect Roche's patent rights while considering the potential impact on GenRx's operations and market competition.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

EMMETT J
GenRx has undertaken not to advertise, or otherwise promote, carvedilol for decreasing mortality except that it will not be a breach of that undertaking to supply copies of the product information sheet in the unamended form. I consider that that undertaking affords a sufficient degree of protection to the Patentees, when coupled with the undertaking to keep proper records of sales of the GenRx products, to justify refusal of interlocutory injunctions. CONCLUSION As I have said, I am not persuaded that I should conclude, at this stage, that there is not a serious question to be tried on infringement of the Patent. Having regard to the matters considered above in deciding where the balance of convenience lies, I consider that it is appropriate to accept the undertakings proffered by GenRx and refuse any further interlocutory relief. However, the Patentees should have liberty to apply on reasonably short notice if, having regard to information furnished pursuant to the undertakings, it wishes to contend that there has been a sufficient change in circumstances to justify revisiting the question of further interlocutory relief. Upon GenRx giving to the Court the undertakings referred to above, the Patentees’ application for interlocutory relief beyond those undertakings should be refused. Some undertakings had been proffered prior to the commencement of the hearing but others were only proffered in the course of argument. In the circumstances, I consider that it would appropriate for GenRx’s costs of the interlocutory application to be GenRx’s costs of the proceeding and that there be no other order as to the costs of the interlocutory application.SCHEDULE1.Subject to the usual undertaking as to damages and without admissions, the respondent undertakes to the Court, until further order:(a)Not to advertise or otherwise promote carvedilol for decreasing mortality resulting from congestive heart failure provided that it will not be a breach of this undertaking for the respondent to advertise or otherwise promote carvedilol in connection with:(i)Product Information Sheet in the form of Exhibit 1A upon request prior to the approval (if granted) of the Product Information in the form of Exhibit AMK-2; or(ii) Consumer Medicine Information in the form of Exhibit RM-7.(b)To prosecute its application for the approval of its Product Information Sheet in the form of Exhibit AMK-2 expeditiously and to inform the applicants at the end of 21 days of the progress of the application.(c)Not to provide any discount or material benefit to purchasers of carvedilol which is tied to the purchase of any other medicament which is also supplied by any of the applicants in Australia.(d)Not to provide any discount or material benefit to purchasers of any other medicament which is also supplied by any of the applicants in Australia which is tied to the purchase of carvedilol.(e)To provide for the benefit of the applicants a guarantee issued by National Australia Bank Limited in the form of Exhibit 10R.(f)To maintain accounts and records of its carvedilol sales until judgment on a final hearing, in the manner described in paragraphs 16 to 19 of the affidavit of Roger Millichamp sworn 9 January 2007.(g)Commencing 30 days after the expiry of the first reporting period (as defined hereafter), to report to the applicants every three months as to the number of units of carvedilol sold in the preceding reporting period and to provide access to the Applicants’ independent legal or accounting representatives to inspect the accounting records referred to in (e), such access to be on reasonable notice and upon the receipt of confidentiality undertaking from those representatives to the effect that they will not disclose to any other person, including the applicants, any information obtained by such inspection other than the number of units of carvedilol sold in the preceding reporting period. The first reporting period expires at the end of the third calendar month following the first supply of carvedilol. (h)Not to seek a decrease in the price at which its carvedilol products are listed on the Schedule of Pharmaceutical Benefits.(i)Within 14 days of the date of this undertaking to request the Pharmaceutical Benefits Advisory Committee to give it and the applicants 14 days’ notice of the imposition of any price reduction for carvedilol and to serve the applicants with a copy of any reply.(j)Not to rely on any commitment to third parties to whom the respondent supplied or intends to supply carvedilol to resist final injunctive relief at a final hearing.

Ratio Decidendi

Legal Principle Established

Established by: EMMETT J

Congestive heart failure may develop gradually over several years or develop quickly as a result of a heart attack or a disease of the heart muscle. Commonly, patients suffering from congestive heart failure suffer fluid retention. The inadequate blood flow results in the release of hormones that result in the body holding on to sodium and water. In the short term, that leads to an increase in blood volume providing the kidneys with sufficient blood for their normal activity. However, over time, the blood vessels of the body cannot hold all of the extra blood volume and fluid starts to exude out of the blood vessels and into the tissues of the body. Such fluid retention is normally treated with a diuretic drug, which increases urine formation and output. REGISTRATION AND LISTING OF PHARMACEUTICAL GOODS A pharmaceutical product may not be marketed, supplied, offered for sale, sold or distributed within Australia unless it is listed or registered on the Register of Therapeutic Goods maintained under the Therapeutic Goods Act 1989 (Cth). The registration for a pharmaceutical product must include at least one indication for the product within Australia. The Pharmaceutical Benefits Scheme is maintained by the Commonwealth under the National Health Act 1953 (Cth) in order to provide all Australian residents with access to subsidised prescription medicines. The Commonwealth Government will only reimburse retail pharmacies for the difference dispensed price of a product and the patient co-payment if a pharmaceutical product is first listed under the Pharmaceutical Benefits Scheme and is prescribed to the patient in accordance with its listed scheme restriction. An Australian pharmaceutical company that manufactures or distributes pharmaceutical products in Australia, termed a sponsor, may apply for listing of any one or more of its prescription pharmaceutical products under the Pharmaceutical Benefits Scheme. However, a pharmaceutical product must be registered on the Register of Therapeutic Goods before listing can occur under the Pharmaceutical Benefits Scheme. The Schedule of Pharmaceutical Benefits (‘the Schedule’) is published by the Department of Health and Aging. It lists all of the pharmaceutical products included under the Pharmaceutical Benefits Scheme. The schedule sets out pricing information, product strengths and the indication or restriction for the product. The primary purpose of the Schedule is to indicate how pharmaceutical products are priced. In order to obtain listing under the Pharmaceutical Benefits Scheme of an innovative pharmaceutical product that contains a new chemical entity as the active compound, the sponsor must lodge a submission to the Pharmaceutical Benefits Advisory Committee (‘the Advisory Committee’). The Advisory Committee is an independent statutory body with the function of recommending to the Minister the drugs and medicinal preparations for subsidy under the Pharmaceutical Benefits Scheme. Comprehensive guidelines are published for the filing of such a submission, including the information required to support such a submission.